<VariationArchive RecordType="classified" VariationID="16914" VariationName="NM_001395413.1(POR):c.559_571dup (p.Arg191fs)" VariationType="Duplication" Accession="VCV000016914" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-05-24" DateCreated="2015-05-08" MostRecentSubmission="2015-05-08">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="31953" VariationID="16914">
      <GeneList>
        <Gene Symbol="POR" FullName="cytochrome p450 oxidoreductase" GeneID="5447" HGNC_ID="HGNC:9208" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7q11.23</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="75915155" stop="75986855" display_start="75915155" display_stop="75986855" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="75544419" stop="75616172" display_start="75544419" display_stop="75616172" Strand="+" />
          </Location>
          <OMIM>124015</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_001395413.1(POR):c.559_571dup (p.Arg191fs)</Name>
      <CanonicalSPDI>NC_000007.14:75981098:TACGTGGACAAGC:TACGTGGACAAGCTACGTGGACAAGC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>7q11.23</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="75981098" stop="75981099" display_start="75981098" display_stop="75981099" variantLength="13" positionVCF="75981098" referenceAlleleVCF="G" alternateAlleleVCF="GTACGTGGACAAGC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="75610416" stop="75610417" display_start="75610416" display_stop="75610417" variantLength="13" positionVCF="75610416" referenceAlleleVCF="G" alternateAlleleVCF="GTACGTGGACAAGC" />
      </Location>
      <ProteinChange>R191fs</ProteinChange>
      <ProteinChange>R209fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001367562.3" sequenceAccession="NM_001367562" sequenceVersion="3" change="c.559_571dup">
            <Expression>NM_001367562.3:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001354491.2" sequenceAccession="NP_001354491" sequenceVersion="2" change="p.Arg191fs">
            <Expression>NP_001354491.2:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001382655.3" sequenceAccession="NM_001382655" sequenceVersion="3" change="c.613_625dup">
            <Expression>NM_001382655.3:c.613_625dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001369584.2" sequenceAccession="NP_001369584" sequenceVersion="2" change="p.Arg209fs">
            <Expression>NP_001369584.2:p.Arg209fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001382657.2" sequenceAccession="NM_001382657" sequenceVersion="2" change="c.559_571dup">
            <Expression>NM_001382657.2:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001369586.2" sequenceAccession="NP_001369586" sequenceVersion="2" change="p.Arg191fs">
            <Expression>NP_001369586.2:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001382658.3" sequenceAccession="NM_001382658" sequenceVersion="3" change="c.559_571dup">
            <Expression>NM_001382658.3:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001369587.2" sequenceAccession="NP_001369587" sequenceVersion="2" change="p.Arg191fs">
            <Expression>NP_001369587.2:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001382659.3" sequenceAccession="NM_001382659" sequenceVersion="3" change="c.559_571dup">
            <Expression>NM_001382659.3:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001369588.2" sequenceAccession="NP_001369588" sequenceVersion="2" change="p.Arg191fs">
            <Expression>NP_001369588.2:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001382662.3" sequenceAccession="NM_001382662" sequenceVersion="3" change="c.559_571dup">
            <Expression>NM_001382662.3:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001369591.2" sequenceAccession="NP_001369591" sequenceVersion="2" change="p.Arg191fs">
            <Expression>NP_001369591.2:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001395413.1" sequenceAccession="NM_001395413" sequenceVersion="1" change="c.559_571dup" MANESelect="true">
            <Expression>NM_001395413.1:c.559_571dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001382342.1" sequenceAccession="NP_001382342" sequenceVersion="1" change="p.Arg191fs">
            <Expression>NP_001382342.1:p.Arg191fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.75610417_75610429dup" Assembly="GRCh37">
            <Expression>NC_000007.13:g.75610417_75610429dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.75981099_75981111dup" Assembly="GRCh38">
            <Expression>NC_000007.14:g.75981099_75981111dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008930.1" sequenceAccession="NG_008930" sequenceVersion="1" change="g.70998_71010dup">
            <Expression>NG_008930.1:g.70998_71010dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA257671" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="124015.0015" DB="OMIM" />
        <XRef Type="rs" ID="786205878" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001395413.1(POR):c.559_571dup (p.Arg191fs) AND Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis" Accession="RCV000018414" Version="25">
        <ClassifiedConditionList TraitSetID="5547">
          <ClassifiedCondition DB="MedGen" ID="C3150099">Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2005-05-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2005-05-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2015-05-08" MostRecentSubmission="2015-05-08">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">14513299</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15793702</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5547" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3367" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">POR Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis</ElementValue>
                <XRef ID="Antley-Bixler+syndrome+with+genital+anomalies+and+disordered+steroidogenesis/7697" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008726" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ABS1</ElementValue>
                <XRef Type="MIM" ID="201750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Cytochrome P450 oxidoreductase deficiency (PORD) is a disorder of steroidogenesis with a broad phenotypic spectrum including cortisol deficiency, altered sex steroid synthesis, disorders of sex development (DSD), and skeletal malformations of the Antley-Bixler syndrome (ABS) phenotype. Cortisol deficiency is usually partial, with some baseline cortisol production but failure to mount an adequate cortisol response in stress. Mild mineralocorticoid excess can be present and causes arterial hypertension, usually presenting in young adulthood. Manifestations of altered sex steroid synthesis include ambiguous genitalia/DSD in both males and females, large ovarian cysts in females, poor masculinization and delayed puberty in males, and maternal virilization during pregnancy with an affected fetus. Skeletal malformations can manifest as craniosynostosis, mid-face retrusion with proptosis and choanal stenosis or atresia, low-set dysplastic ears with stenotic external auditory canals, hydrocephalus, radiohumeral synostosis, neonatal fractures, congenital bowing of the long bones, joint contractures, arachnodactyly, and clubfeet; other anomalies observed include urinary tract anomalies (renal pelvic dilatation, vesicoureteral reflux). Cognitive impairment is of minor concern and likely associated with the severity of malformations; studies of developmental outcomes are lacking.</Attribute>
                <XRef ID="NBK1419" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301592</ID>
                <ID Source="BookShelf">NBK1419</ID>
              </Citation>
              <XRef ID="63269" DB="Orphanet" />
              <XRef ID="C3150099" DB="MedGen" />
              <XRef ID="MONDO:0008726" DB="MONDO" />
              <XRef Type="MIM" ID="201750" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="38696" SubmissionDate="2015-05-01" DateLastUpdated="2015-05-08" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="124015.0015_ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS" title="POR, 13-BP INS, NT580_ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS" />
        <ClinVarAccession Accession="SCV000038696" DateUpdated="2015-05-08" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2005-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a male infant with skeletal findings of Antley-Bixler syndrome and abnormal steroids and genitalia (ABS1; 201750), in whom Hurley et al. (2004) had previously found a heterozygous missense mutation of unclear significance in the FGFR1 gene (136350.0011), Huang et al. (2005) identified compound heterozygosity for a 13-bp insertion (580insTACGTGGACAAGC) and a gly539-to-arg (G539R; 124015.0016) substitution in the POR gene. The frameshift was predicted to disrupt the flavin mononucleotide (FMN)- and NADPH-binding sites and to result in premature termination of the protein. Functional studies showed that the G539R mutant retained 46% of the 17-alpha-hydroxylase activity but only 8% of the 17,20 lyase activity; consistent with this, the patient was able to synthesize cortisol adequately (17-alpha-hydrolase activity) but had poor production of sex steroids (17,20 lyase activity).</Attribute>
              <Citation>
                <ID Source="PubMed">14513299</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">15793702</ID>
              </Citation>
              <XRef DB="OMIM" ID="201750" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POR" />
          </GeneList>
          <Name>POR, 13-BP INS, NT580</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">13-BP INS, NT580</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="124015.0015" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="38696" TraitType="Disease" MappingType="Name" MappingValue="ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS" MappingRef="Preferred">
        <MedGen CUI="C3150099" Name="Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

